Company Encyclopedia
View More
name
MEDISAN
002900.SZ
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium folinate for injection, hydroxylcamptothecine injection, tropisetron hydrochloride for injection, tropisetron hydrochloride and glucose injection, gabexate mesylate for injection, bismuth potassium citrate granules, pantoprazole sodium for injection, ambroxol hydrochloride and glucose injection, asarone for injection, paracetamol and tramadol hydrochloride tablets, rifamycin sodium for injection, lornoxicam for injection, vecuronium bromide for injection, and vitamin c for injection. It also provides medical devices and cosmetics.
3.159 T
002900.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking200/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-9.43%D
    • Profit Margin-21.81%E
    • Gross Margin46.94%B
  • Growth ScoreE
    • Revenue YoY-20.70%E
    • Net Profit YoY-452.44%E
    • Total Assets YoY1.53%C
    • Net Assets YoY-11.22%D
  • Cash ScoreE
    • Cash Flow Margin-458.51%E
    • OCF YoY-20.70%E
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreC
    • Gearing Ratio47.22%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    MEDISAN: The company's drugs, Rosuvastatin capsules and Chlorpromazine for injection, are expected to win the bid

    MEDISAN announced that the company recently participated in the bidding work organized by the National Organization for Drug Procurement Office for the 11th batch of national centralized drug procurement. The company's drugs, Rosuvastatin capsules and injectable Clonixin, are expected to win the bid in this centralized procurement

    Zhitong·
    SZ
    002900
    -3.79%
    Zhitong·
    SZ
    002900
    -3.79%

    The innovative drug concept strengthened at the beginning of the trading session, with MEDISAN and ALK both hitting the daily limit

    The innovative drug concept strengthened at the beginning of the trading session, with MEDISAN and ALK both hitting the daily limit, followed by gains in Shutaishen, Asia-Pacific Pharmaceutical, Duoyi Pharmaceutical, Yipinhong, Shanghai Yizhong, and Jinshiya Pharmaceutical

    Zhitong·
    SZ
    002900
    -3.79%
    SZ
    002940
    -1.44%
    Zhitong·
    SZ
    002900
    -3.79%
    SZ
    002940
    -1.44%

    Zhitong A-share lock-up release overview | September 30

    On September 30th, a total of 5 listed companies had their restricted shares unlocked, with a total market value of approximately 7.641 billion yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Share Quantity FRONTOP 301313 Pre-issue Share Restricted Circulation 33.5425 million MEDISAN 002900 Equity Incentive Restricted Circulation 1.9816 million OJing Tech 001269 Pre-issue Share Restricted Circulation 1.09 million BOFAY 001255 Pre-issue Share Restricted Circulation 6 million UIGreen 688661 1.4112 million

    Zhitong·
    SZ
    001269
    +0.17%
    SH
    688661
    +7.94%
    SZ
    001255
    +1.31%
    Zhitong·
    SZ
    001269
    +0.17%
    SH
    688661
    +7.94%
    SZ
    001255
    +1.31%

    MEDISAN Pharmaceuticals: In the third phase of the 2022 incentive plan, 166 individuals can lift the sales restrictions

    Harbin Sanlian Pharmaceutical Co., Ltd. Supervisory Board reviewed the list of individuals eligible for the lifting of restrictions under the third phase of the 2022 restricted stock incentive plan and confirmed that 166 incentive recipients meet the conditions for lifting restrictions. The Supervisory Board agreed to lift restrictions on 1,963,555 shares of restricted stock for these 166 incentive recipients, with the announcement date set for September 17, 2025

    Zhitong·
    SZ
    002900
    -3.79%
    Zhitong·
    SZ
    002900
    -3.79%

    MEDISAN released its performance for the first half of the year, turning from profit to a loss of 92.3904 million yuan

    According to the Zhitong Finance APP, MEDISAN released its semi-annual report for 2025. During the reporting period, the company achieved operating revenue of 413 million yuan, a year-on-year decrease of 21.08%. The net loss attributable to shareholders of the listed company was 92.3904 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 89.1959 million yuan. The basic loss per share was 0.29 yuan

    Zhitong·
    SZ
    002900
    -3.79%
    Zhitong·
    SZ
    002900
    -3.79%
    © 2025 Longbridge｜Disclaimer